Chris Mazzolini

1 month ago | patientcareonline.com | Chris Mazzolini |Jeff Andrews

Cervical cancer remains largely preventable, yet screening gaps persist in the United States.

Oct 11, 2024 | conciergemedicinetoday.org | Chris Mazzolini

Explore concierge medicine’s auspicious beginnings and why the future looks exceptionally bright for personalized care models in this lively conversation with industry pioneers Terry Bauer, CEO of Specialdocs Consultants, and Michael Tetreault, Forum organizer and editor of Concierge Medicine Today. September 30, 2024By Chris Mazzolini, Medical EconomicsStart with our video series designed to give you a sneak peek of intriguing sessions on the CMF agenda.

Oct 4, 2024 | medicaleconomics.com | Chris Mazzolini

Two experts discuss how emerging trends in health care — market conditions, consolidation, the physician shortage and more — are impacting physician liability risks.

Oct 2, 2024 | conciergemedicinetoday.org | Chris Mazzolini

National Headlines Explore concierge medicine’s auspicious beginnings and why the future looks exceptionally bright for personalized care models in this lively conversation with industry pioneers Terry Bauer, CEO of Specialdocs Consultants, and Michael Tetreault, Forum organizer and editor of Concierge Medicine Today. September 30, 2024By Chris Mazzolini, Medical EconomicsStart with our video series designed to give you a sneak peek of intriguing sessions on the CMF agenda.

Mar 21, 2024 | patientcareonline.com | Chris Mazzolini

On March 20, 2024, The US Food and Drug Administration (FDA) approved aprocitentan (Tryvio) as concomitant treatment for hypertension in adults whose blood pressure (BP) is not adequately controlled by other medications. Tryvio, from drugmaker Idorsia, is the first antihypertensive therapy to be approved in nearly 4 decades that delivers its BP-lowering effect through a novel mechanism of action. The drug will be available to patients in the second half of 2024, the company said.